CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech that has worked diligently but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix. In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked diligently but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn's inventories of leronlimab are building up, whether they'll ever be used is actually an open question.


While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last few shares. My 1st CytoDyn article, "CytoDyn: What to be able to Do When It's Too Good to be able to Be True?", set away what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview that I came away with a poor viewpoint of the business.

Irony of irony, the poor opinion of mine of the business enterprise has grown steadily, though the disappointment hasn't been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today's transaction of $3.5 million transfers ownership of the expertise as well as connected intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 zillion) as well as the first new drug program approval ($5 million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn's helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it has this individual treatment in addition to a "broad pipeline of indications" because it places it. I call such pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Can all this be smoke and mirrors? That's a question I have been asking myself from the really beginning of my interest in this company. Judging with the multiples of a huge number of diverse responses on listings accessible via Seeking Alpha's CytoDyn Summary webpage, I'm a lot from alone in this question.

CytoDyn is a traditional battleground, or perhaps some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *